# FHD-909 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fhd-909

> FHD-909, sponsored by Foghorn Therapeutics Inc. (FHTX): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | FHD-909 |
| Codes | FHD-909, LY4050784 |
| Sponsor | Foghorn Therapeutics Inc. (FHTX) https://sec-api.dev/companies/fhtx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-01-13, last confirmed 2025-03-06.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010916): "Dosed first patient with FHD-909 in October 2024." https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/ex991earningspressrelease3.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010916): "The first patient was dosed with FHD-909 in the Phase 1 open-label, multicenter trial for SMARCA4 mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population, in October 2024." https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/ex991earningspressrelease3.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010916): "First patient dosed in October 2024 in the Phase 1 trial for FHD-909 in SMARCA4 mutated cancers, with NSCLC as the primary target population." https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/ex991earningspressrelease3.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001226): "First patient dosed in October 2024 in the Phase 1 trial for FHD-909 in SMARCA4 mutated cancers, with NSCLC as the primary target population." https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/ex991pressreleaseissuedonj.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fhd-909.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FHD-909 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fhd-909

```bibtex
@misc{secapidev_pdufa_fhd_909_20261116,
  title        = {FHD-909 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fhd-909}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fhd_909_20261116","title":"FHD-909 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fhd-909","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
